Craft

Pacira Pharmaceuticals

Stock Price

$17.2

2024-10-29

Market Capitalization

$792.5 M

2024-10-29

Revenue

$726.4 M

FY, 2025

Pacira Pharmaceuticals Summary

Company Summary

Overview
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product includes EXPAREL, is a non-opioid local analgesic indicated for administration into the surgical site to produce postsurgical analgesia. EXPAREL combines bupivacaine with the DepoFoam to provide postsurgical pain control with a single intraoperative infiltration.
Type
Public
Status
Active
Founded
2006
HQ
Parsippany-Troy Hills, NJ, US | view all locations
Website
http://www.pacira.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • David Stack

    David Stack, Chief Executive Officer and Chairman

    • Paul J Hastings, Director

      • Kristen Williams

        Kristen Williams, Chief Administrative Officer and Secretary

      • Max Reinhardt

        Max Reinhardt, President, Rest of World

      LocationsView all

      6 locations detected

      • Parsippany-Troy Hills, NJ HQ

        United States

        5 Sylvan Way, Parsippany

      • Fremont, CA

        United States

        46400 Fremont Blvd

      • San Diego, CA

        United States

        10578 Science Center Dr #125

      • Tampa, FL

        United States

        5401 W Kennedy Blvd

      • Swindon, England

        United Kingdom

        Kingfisher Dr

      Pacira Pharmaceuticals Financials

      Summary Financials

      Revenue (Q1, 2026)
      $177.4M
      Gross profit (Q1, 2026)
      $141.0M
      Net income (Q1, 2026)
      $2.9M
      Cash (Q1, 2026)
      $144.3M
      EBIT (Q1, 2026)
      $6.9M
      Enterprise value
      $1.1B

      Footer menu